product name RGD (Arg-Gly-Asp)
Description: RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins. RGD peptide can induce apoptosis in the absence of signals and integrin-mediated cell clustering. Previous study demonstrates that RGD peptides promote apoptosis through activation of conformation changes enhancing pro-caspase-3 activation and autoprocessing.
References: Annu Rev Cell Dev Biol. 1996;12:697-715; Nature. 1999 Feb 11;397(6719):534-9.
346.34
Formula
C12H22N6O6
CAS No.
99896-85-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 12 mg/mL (34.6 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: The RGD sequence is the cell attachment site of a large number of adhesive extracellular matrix, blood, and cell surface proteins, and nearly half of the over 20 known integrins recognize this sequence in their adhesion protein ligands. The RGD peptides and mimics can be used to probe integrin functions in various biological systems. Drug design based on the RGD structure may provide new treatments for diseases such as thrombosis, osteoporosis, and cancer. RGD peptide acts as an inhibitor of integrin-ligand interactions and can induce apoptosis in the absence of signals and integrin-mediated cell clustering. Research demonstrates that RGD peptides promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. The RGD peptide can serve as a cell adhesion site of extracellular matrix, cell surface proteins, and integrins. In addition, RGD peptide can inhibit ACK-2 activation through cell adhesion. Kinase Assay: Cell Assay: RGD peptide can induce apoptosis in the absence of signals and integrin-mediated cell clustering. Previous study demonstrates that RGD peptides promote apoptosis through activation of conformation changes enhancing pro-caspase-3 activation and autoprocessing. |
|---|---|
| In Vivo | Anima study suggested that the RGD-4C-FITC-peptide bound to both endothelial and tumor cells in vivo and that peptide targeting should allow the delivery of therapeutic drugs to both endothelial and tumor cells. |
| Animal model | |
| Formulation & Dosage | |
| References | Annu Rev Cell Dev Biol. 1996;12:697-715; Nature. 1999 Feb 11;397(6719):534-9. |
